U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C18H20FN3O4.H2O
Molecular Weight 740.7503
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEVOFLOXACIN

SMILES

O.C[C@H]1COC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N4CCN(C)CC4.C[C@H]5COC6=C7N5C=C(C(O)=O)C(=O)C7=CC(F)=C6N8CCN(C)CC8

InChI

InChIKey=SUIQUYDRLGGZOL-RCWTXCDDSA-N
InChI=1S/2C18H20FN3O4.H2O/c2*1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21;/h2*7-8,10H,3-6,9H2,1-2H3,(H,24,25);1H2/t2*10-;/m00./s1

HIDE SMILES / InChI

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C18H20FN3O4
Molecular Weight 361.3675
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Levofloxacin is the L-isomer of the racemate, ofloxacin, a quinolone antimicrobial agent. Levofloxacin is used for oral and intravenous administration. Levofloxacin is sold under brand name levaquin and is used to treat infections in adults (≥18 years of age) caused by designated, susceptible bacteria such as, pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. In addition this drug is used to treat plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis. Levofloxacin, like other fluoroquinolones, inhibits the bacterial DNA gyrase, halting DNA replication. This results in strand breakage on a bacterial chromosome, supercoiling, and resealing. In addition, levofloxacin inhibits a bacterial type II topoisomerase.

CNS Activity

Curator's Comment: levofloxacin penetrates the cerebrospinal fluid (CSF) during meningeal inflammation both in animals and in humans

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
LEVAQUIN

Approved Use

LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis.

Launch Date

8.5104001E11
Curative
LEVAQUIN

Approved Use

LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis.

Launch Date

8.5104001E11
Curative
LEVAQUIN

Approved Use

LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis.

Launch Date

8.5104001E11
Curative
LEVAQUIN

Approved Use

LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis.

Launch Date

8.5104001E11
Curative
LEVAQUIN

Approved Use

LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis.

Launch Date

8.5104001E11
Curative
LEVAQUIN

Approved Use

LEVAQUIN is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria. Pneumonia: nosocomial and community acquired; skin and skin structure infections: complicated and uncomplicated; chronic bacterial prostatitis; inhalational anthrax. Post-Exposure and plague; urinary tract infections: complicated and uncomplicated; acute pyelonephritis; acute bacterial exacerbation of chronic bronchitis and acute bacterial sinusitis.

Launch Date

8.5104001E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.9 mg/L
500 mg 2 times / day multiple, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.8 mg/L
500 mg 2 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
11.8 mg/L
1000 mg 1 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8.85 mg/L
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
2.04 mg/L
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6.3 mg/L
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
49.6 mg × h/L
500 mg 2 times / day multiple, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
59 mg × h/L
500 mg 2 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
118 mg × h/L
1000 mg 1 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
111 mg × h/L
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
19.88 mg × h/L
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
55.3 mg × h/L
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.6 h
500 mg 2 times / day multiple, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8.4 h
500 mg 2 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
8.9 h
1000 mg 1 times / day multiple, oral
dose: 1000 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
7.9 h
1000 mg single, oral
dose: 1000 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
5.97 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6.6 h
500 mg single, intravenous
dose: 500 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LEVOFLOXACIN unknown
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
250 mg 1 times / day multiple, oral
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Disc. AE: Gastrointestinal disorder, Nausea...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorder (1.4%)
Nausea (0.6%)
Vomiting (0.4%)
Dizziness (0.3%)
Headache (0.2%)
Sources: Page: 19
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Disc. AE: Gastrointestinal disorder, Nausea...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorder (1.4%)
Nausea (0.6%)
Vomiting (0.4%)
Dizziness (0.3%)
Headache (0.2%)
Sources: Page: 19
750 mg 1 times / day steady, oral
Recommended
Dose: 750 mg, 1 times / day
Route: oral
Route: steady
Dose: 750 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Disc. AE: Gastrointestinal disorder, Nausea...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorder (1.2%)
Nausea (0.6%)
Vomiting (0.5%)
Dizziness (0.3%)
Headache (0.3%)
Sources: Page: 19
AEs

AEs

AESignificanceDosePopulation
Headache 0.2%
Disc. AE
250 mg 1 times / day multiple, oral
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Dizziness 0.3%
Disc. AE
250 mg 1 times / day multiple, oral
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Vomiting 0.4%
Disc. AE
250 mg 1 times / day multiple, oral
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Nausea 0.6%
Disc. AE
250 mg 1 times / day multiple, oral
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Gastrointestinal disorder 1.4%
Disc. AE
250 mg 1 times / day multiple, oral
Recommended
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Headache 0.2%
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Dizziness 0.3%
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Vomiting 0.4%
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Nausea 0.6%
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Gastrointestinal disorder 1.4%
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Dizziness 0.3%
Disc. AE
750 mg 1 times / day steady, oral
Recommended
Dose: 750 mg, 1 times / day
Route: oral
Route: steady
Dose: 750 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Headache 0.3%
Disc. AE
750 mg 1 times / day steady, oral
Recommended
Dose: 750 mg, 1 times / day
Route: oral
Route: steady
Dose: 750 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Vomiting 0.5%
Disc. AE
750 mg 1 times / day steady, oral
Recommended
Dose: 750 mg, 1 times / day
Route: oral
Route: steady
Dose: 750 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Nausea 0.6%
Disc. AE
750 mg 1 times / day steady, oral
Recommended
Dose: 750 mg, 1 times / day
Route: oral
Route: steady
Dose: 750 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
Gastrointestinal disorder 1.2%
Disc. AE
750 mg 1 times / day steady, oral
Recommended
Dose: 750 mg, 1 times / day
Route: oral
Route: steady
Dose: 750 mg, 1 times / day
Sources: Page: 19
unhealthy, mean 50 years
n = 7537
Health Status: unhealthy
Condition: infectious diseases
Age Group: mean 50 years
Sex: M+F
Population Size: 7537
Sources: Page: 19
OverviewDrug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
yes [Km 136 uM]
yes
yes
yes
yes
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
1999 Dec
Levofloxacin.
1999 Nov
Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae.
1999 Oct
Antimycobacterial activities of novel levofloxacin analogues.
2000 Aug
Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
2000 Feb
In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials.
2000 Jan
The 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors.
2000 Jul
Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.
2000 May
Anti-toxoplasma activities of 24 quinolones and fluoroquinolones in vitro: prediction of activity by molecular topology and virtual computational techniques.
2000 Oct
Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.
2000 Sep
In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs.
2000 Sep
A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
2001
Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.
2001
The role of fluoroquinolones in tuberculosis today.
2001
Enantioseparation of ofloxacin in urine by capillary electrokinetic chromatography using charged cyclodextrins as chiral selectors and assessment of enantioconversion.
2001 Apr
Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects.
2001 Apr
Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis.
2001 Apr
[Use of levofloxacine in primary care for outbreaks in COPD].
2001 Apr 15
A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae.
2001 Aug 15
Quinolones alter defense reactions mediated by macrophages.
2001 Feb
Impact of gemifloxacin on the normal human intestinal microflora.
2001 Feb
Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin.
2001 Feb
Lack of interaction between levofloxacin and oxycodone: pharmacokinetics and drug disposition.
2001 Feb
In vitro activity of new quinolones against Clostridium difficile.
2001 Feb
Novel treatment of meningitis caused by multidrug-resistant Mycobacterium tuberculosis with intrathecal levofloxacin and amikacin: case report.
2001 Feb 15
Effects of common topical otic preparations on the morphology of isolated cochlear outer hair cells.
2001 Jan
In vitro and in vivo antimicrobial activity of topical ofloxacin and other ototopical agents.
2001 Jan
In vitro activity of ketolides HMR 3004 and HMR 3647 and seven other antimicrobial agents against Corynebacterium diphtheriae.
2001 Jan
Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp.
2001 Jul
Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams.
2001 Jul
The use of fluoroquinolones as antiinfective transition-therapy agents in community-acquired pneumonia.
2001 Jul
Levofloxacin and warfarin interaction.
2001 Jul
Activity of levofloxacin and ciprofloxacin against urinary pathogens.
2001 Jul
Comparison of in-vitro activities of SCH27899 and other antibiotics against Mycoplasma pneumoniae.
2001 Jun
Complicated urinary tract infections in patients with voiding dysfunction.
2001 Jun
Effect of levofloxacin on theophylline clearance during theophylline and clarithromycin combination therapy.
2001 Jun
Levofloxacin failure in a patient with pneumococcal pneumonia.
2001 Jun
Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.
2001 Jun
Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.
2001 Jun
Activity of oral agents against pediatric isolates of Streptococcus pneumoniae.
2001 Mar
Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials.
2001 Mar
In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis.
2001 Mar
Clinical perspectives on new antimicrobials: focus on fluoroquinolones.
2001 Mar 15
Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model.
2001 Mar 15
Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.
2001 May
Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.
2001 May
Abiotrophia bacteremia in a patient with neutropenic fever and antimicrobial susceptibility testing of Abiotrophia isolates.
2001 May 15
Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States.
2001 May-Jun
Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
2001 May-Jun
Activity of BMS284756 (T-3811) tested against anaerobic bacteria, Campylobacter jejuni, Helicobacter pylori and Legionella spp.
2001 May-Jun
Patents

Sample Use Guides

The usual dose of LEVAQUIN tablets or oral solution is 250 mg, 500 mg, or 750 mg administered orally every 24 hours. The usual dose of LEVAQUIN Injection is 250 mg or 500 mg administered by slow infusion over 60 minutes every 24 hours or 750 mg administered by slow infusion over 90 minutes every 24 hours. Nosocomial Pneumonia: 750 mg during 7–14 days Community Acquired Pneumonia: 500 mg during 7–14 days Community Acquired Pneumonia§ 750 mg during 5 days Complicated Skin and Skin Structure Infections (SSSI) 750 mg during 7–14 days Uncomplicated SSSI 500 mg during 7–10 days Chronic Bacterial Prostatitis 500 mg during 28 days Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) 750 mg during 5 days Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) 250 mg during 10 days Uncomplicated Urinary Tract Infection 250 mg 3 during days Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) 500 mg during 7 days Acute Bacterial Sinusitis (ABS) 750 mg days or 500 mg during 10–14 days.
Route of Administration: Other
In Vitro Use Guide
Levofloxacin was compared to ofloxacin and ciprofloxacin against > 6000 recent clinical isolates of Gram-positive and Gram-negative bacteria from six different countries. This international multicenter study demonstrated a high level of antibacterial activity of levofloxacin against all the members of Enterobacteriaceae [minimum inhibitory concentration (MIC)50s, < or = 0.03 to 0.12 mg/L] except Providencia rettgeri (MIC50, 2 mg/L), and Providencia stuartii (MIC50, 1 mg/L). Levofloxacin was also active against non-enteric Gram-negative bacilli, including Acinetobacter species (MIC50s, < or = 0.03 to 1 mg/L), Pseudomonas species (MIC50s, 0.5 to 1 mg/L) and Xanthomonas maltophilia (MIC50, 0.5 mg/L). Overall, levofloxacin inhibited 50% and 90% of all the tested strains at the concentrations of 0.12 and 4 mg/L, respectively. The activity of levofloxacin was generally two-fold greater than ofloxacin and equal to or slightly less potent than ciprofloxacin.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:30:28 UTC 2023
Edited
by admin
on Fri Dec 15 15:30:28 UTC 2023
Record UNII
6GNT3Y5LMF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LEVOFLOXACIN
MART.   ORANGE BOOK   USAN   USP-RS   VANDF  
USAN  
Official Name English
OFLOXACIN S-(-)-FORM HEMIHYDRATE [MI]
Common Name English
(-)-(S)-9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-7H-PYRIDO(1,2,3-DE)-1,4-BENZOXAZINE-6-CARBOXYLIC ACID, HEMIHYDRATE
Common Name English
LEVOFLOXACIN [VANDF]
Common Name English
LEVOFLOXACIN HYDRATE [JAN]
Common Name English
LEVOFLOXACIN HYDRATE
JAN  
Common Name English
LEVOFLOXACIN [ORANGE BOOK]
Common Name English
CRAVIT
Brand Name English
LEVOFLOXACIN [USP MONOGRAPH]
Common Name English
VOLEQUIN
Brand Name English
QUINSAIR
Brand Name English
IQUIX
Brand Name English
QUIXIN
Brand Name English
LEVOFLOXACIN HEMIHYDRATE
WHO-DD  
Common Name English
LEVAQUIN
Brand Name English
RWJ-25213
Code English
TAVANIC
Brand Name English
LEVOFLOXACIN HEMIHYDRATE [EP MONOGRAPH]
Common Name English
L-OFLOXACIN
Common Name English
DR-3355
Code English
7H-PYRIDO(1,2,3-DE)-1,4-BENZOXAZINE-6-CARBOXYLIC ACID, 9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-1-PIPERAZINYL)-7-OXO-HYDRATE (2:1), (S)-
Common Name English
LEVOFLOXACIN (AS HEMIHYDRATE)
Common Name English
Levofloxacin hemihydrate [WHO-DD]
Common Name English
OFLOXACIN, (S)-
Common Name English
LEVOFLOXACIN [USP-RS]
Common Name English
LEVOFLOXACIN [USAN]
Common Name English
NOFAXIN
Brand Name English
LEVOFLOXACIN [MART.]
Common Name English
Classification Tree Code System Code
WHO-ATC S01AE05
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
WHO-ATC A02BD10
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
NDF-RT N0000007606
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
FDA ORPHAN DRUG 253707
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
WHO-ATC J01MA12
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
LIVERTOX NBK548357
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
NDF-RT N0000175937
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
NCI_THESAURUS C795
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
EU-Orphan Drug EU/3/08/566
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
WHO-VATC QS01AE05
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
WHO-VATC QJ01RA05
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
WHO-ATC J01RA05
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
EMA ASSESSMENT REPORTS QUINSAIR (AUTHORIZED: CYSTIC FIBROSIS)
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
WHO-VATC QJ01MA12
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C1586
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
RS_ITEM_NUM
1362103
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
FDA UNII
6GNT3Y5LMF
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
DAILYMED
6GNT3Y5LMF
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
WIKIPEDIA
LEVOFLOXACIN
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
EPA CompTox
DTXSID60160533
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
DRUG CENTRAL
1569
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
CHEBI
63598
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
USAN
II-30
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
EVMPD
SUB21640
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
CAS
138199-71-0
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
MERCK INDEX
m8133
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
SMS_ID
100000091529
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
PUBCHEM
3033924
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
LACTMED
Levofloxacin
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
DRUG BANK
DB01137
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
RXCUI
82122
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY RxNorm
ChEMBL
CHEMBL33
Created by admin on Fri Dec 15 15:30:29 UTC 2023 , Edited by admin on Fri Dec 15 15:30:29 UTC 2023
PRIMARY
Related Record Type Details
BINDER->LIGAND
ROUTE OF ADMINISTRATION: ORAL AND INJECTION
BINDING
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
PARENT -> SALT/SOLVATE
ANHYDROUS->SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MIC PHARMACOKINETIC SUSCEPTIBILITY: RESISTANT

PATHOGEN: ENTEROBACTERIACEAE, E. FAECALIS, STAPHYLOCOCCUS SPECIES, P. AERUGINOSA, S. PNEUMONIAE, S. PYOGENES

MIC BIOLOGICAL SUSCEPTIBILITY: SUSCEPTIBLE

PATHOGEN: ENTEROBACTERIACEAE, E. FAECALIS, STAPHYLOCOCCUS SPECIES, P. AERUGINOSA, H. INFLUENZAE, H. PARAINFLUENZAE, S. PNEUMONIAE, S. PYOGENES

Volume of Distribution PHARMACOKINETIC POPULATION: INFANTS ≥ 6 MONTHS, CHILDREN, AND ADOLESCENTS ≤ 16 YEARS

Biological Half-life PHARMACOKINETIC POPULATION: CHILDREN 12-16 YEARS

Biological Half-life PHARMACOKINETIC POPULATION: CHILDREN 5-10 YEARS

Tmax PHARMACOKINETIC
MIC PHARMACOKINETIC SUSCEPTIBILITY: SUSCEPTIBLE

PATHOGEN: YERSINIA PESTIS, BACILLUS ANTHRACIS

Biological Half-life PHARMACOKINETIC POPULATION: ADULTS WITH RENAL IMPAIRMENT (CrCL < 20 ML/MIN)

Biological Half-life PHARMACOKINETIC POPULATION: CHILDREN 10-12 YEARS

ORAL BIOAVAILABILITY PHARMACOKINETIC ROUTE OF ADMINISTRATION: ORAL

Biological Half-life PHARMACOKINETIC POPULATION: ADULTS WITH RENAL IMPAIRMENT (CrCL 20-49 ML/MIN)

Volume of Distribution PHARMACOKINETIC POPULATION: ADULTS

Biological Half-life PHARMACOKINETIC POPULATION: INFANTS ≥ 6 MONTHS AND CHILDREN ≤ 5 YEARS

Biological Half-life PHARMACOKINETIC POPULATION: ADULTS

MIC PHARMACOKINETIC SUSCEPTIBILITY: INTERMEDIATE

PATHOGEN: ENTEROBACTERIACEAE, E. FAECALIS, STAPHYLOCOCCUS SPECIES, P. AERUGINOSA, S. PNEUMONIAE, S. PYOGENES